Patents by Inventor Wen Fury
Wen Fury has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240084293Abstract: Cas-protein-ready tau biosensor cells, CRISPR/Cas synergistic activation mediator (SAM)-ready tau biosensor cells, and methods of making and using such cells to screen for genetic modifiers of tau seeding or aggregation are provided. Reagents and methods for sensitizing such cells to tau seeding activity or tau aggregation or for causing tau aggregation are also provided.Type: ApplicationFiled: November 6, 2023Publication date: March 14, 2024Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Marine Prissette, Matthew Koss, Wen Fury, Brian Zambrowicz
-
Patent number: 11845931Abstract: Cas-protein-ready tau biosensor cells, CRISPR/Cas synergistic activation mediator (SAM)-ready tau biosensor cells, and methods of making and using such cells to screen for genetic modifiers of tau seeding or aggregation are provided. Reagents and methods for sensitizing such cells to tau seeding activity or tau aggregation or for causing tau aggregation are also provided.Type: GrantFiled: March 17, 2020Date of Patent: December 19, 2023Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Marine Prissette, Matthew Koss, Wen Fury, Brian Zambrowicz
-
Patent number: 11845930Abstract: Methods and systems for CRISPR positive selection are described. CRISPR positive selection uses DNA sequencing to identify genes that their perturbation by CRISPR guide RNAs is correlated to the phenotype. In some aspects, disclosed are genome-wide CRISPR/Cas9 screening methods to identify genetic modifiers. Also disclosed are the apparatuses used for performing the methods.Type: GrantFiled: March 17, 2020Date of Patent: December 19, 2023Assignee: Regeneron Pharmaceuticals Inc.Inventors: Wen Fury, Yu Bai
-
Publication number: 20230293727Abstract: Provided herein are methods of inhibiting tau aggregation in a cell or a subject, comprising administering a LEM domain-containing protein 2 (LEMD2), a charged multivesicular body protein 7 (CHMP7), or an inner nuclear membrane protein Man 1 (LEMD3) or a nucleic acid encoding the LEMD2, the CHMP7, or the LEMD3 to the cell or the subject. Also provided herein are methods of treating or preventing a tauopathy in a subject, comprising administering LEMD2, CHMP7, or LEMD3 or a nucleic acid encoding the LEMD2, the CHMP7, or the LEMD3 to the subject, wherein the LEMD2, the CHMP7, or the LEMD3 inhibits tau aggregation in a cell in the subject. Also provided are nucleic acids encoding LEMD2, CHMP7, or LEMD3 (e.g., in an expression construct and operably linked to a heterologous promoter).Type: ApplicationFiled: October 26, 2022Publication date: September 21, 2023Inventors: Marine Prissette, Wen Fury, Daria Fedorova, Claudia Racioppi, Brian Zambrowicz
-
Patent number: 11594302Abstract: Provided herein are methods for accurately determining the alleles present at a locus that is broadly applicable to any locus, including highly polymorphic loci such as HLA loci, BGA loci and HV loci. Embodiments of the disclosed methods are useful in a wide range of applications, including, for example, organ transplantation, personalized medicine, diagnostics, forensics and anthropology.Type: GrantFiled: October 19, 2018Date of Patent: February 28, 2023Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Yu Bai, Wen Fury
-
Publication number: 20210403567Abstract: The present disclosure provides methods for treating, reducing the severity of, or inhibiting the growth of a tumor or improving overall survival in a cervical cancer patient, wherein the method includes selecting a patient with cervical cancer in need thereof and administering to the patient a therapeutically effective amount of a programmed death 1 (PD-1) inhibitor (e.g., an anti-PD-1 antibody or antigen-binding fragment thereof such as cemiplimab or a bioequivalent thereof). In certain embodiments, the patient has recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.Type: ApplicationFiled: May 25, 2021Publication date: December 30, 2021Inventors: Matthew G. Fury, Israel Lowy, Melissa Divya Mathias, Nazumi Alice Yama-Dang, Wen Fury
-
Publication number: 20210142867Abstract: This disclosure relates to methods for deconvolving bulk or spatial RNA-sequencing data, computer readable medium storing processor-executable instructions adapted to deconvolve bulk or spatial RNA-sequencing data, and systems for deconvolving bulk or spatial RNA-sequencing data to characterize cell type compositions.Type: ApplicationFiled: November 6, 2020Publication date: May 13, 2021Inventors: Tao Yang, Yu Bai, Wen Fury, Gurinder Atwal
-
Patent number: 10851158Abstract: The present invention relates to the identification of certain biomarkers for use in identifying patients who have, or are likely to develop an IL-33 mediated disease or disorder and who are more likely to respond to therapy with an IL-33 antagonist. The invention also relates to methods of treatment of an IL-33-mediated disease or disorder in a patient by administering an IL-33 antagonist to the patient in need thereof and monitoring the effectiveness of therapy using the biomarkers described herein. Also provided are methods for decreasing the level of at least one biomarker in a subject suffering from an IL-33-mediated disease or disorder, and methods for treating such diseases or disorders according to the expression levels of one or more biomarkers. The methods of the present invention comprise administering to a subject in need thereof a pharmaceutical composition comprising an interleukin-33 antagonist.Type: GrantFiled: May 21, 2018Date of Patent: December 1, 2020Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Jamie M. Orengo, Jeanne Allinne, Wen Fury, Yu Bai
-
Publication number: 20200299679Abstract: Methods and systems for CRISPR positive selection are described. CRISPR positive selection uses DNA sequencing to identify genes that their perturbation by CRISPR guide RNAs is correlated to the phenotype.Type: ApplicationFiled: March 17, 2020Publication date: September 24, 2020Inventors: Wen Fury, Yu Bai
-
Publication number: 20200299682Abstract: Cas-protein-ready tau biosensor cells, CRISPR/Cas synergistic activation mediator (SAM)-ready tau biosensor cells, and methods of making and using such cells to screen for genetic modifiers of tau seeding or aggregation are provided. Reagents and methods for sensitizing such cells to tau seeding activity or tau aggregation or for causing tau aggregation are also provided.Type: ApplicationFiled: March 17, 2020Publication date: September 24, 2020Inventors: Marine Prissette, Matthew Koss, Wen Fury, Brian Zambrowicz
-
Publication number: 20190121940Abstract: Provided herein are methods for accurately determining the alleles present at a locus that is broadly applicable to any locus, including highly polymorphic loci such as HLA loci, BGA loci and HV loci. Embodiments of the disclosed methods are useful in a wide range of applications, including, for example, organ transplantation, personalized medicine, diagnostics, forensics and anthropology.Type: ApplicationFiled: October 19, 2018Publication date: April 25, 2019Inventors: Yu Bai, Wen Fury
-
Patent number: 10162933Abstract: Provided herein are methods for accurately determining the alleles present at a locus that is broadly applicable to any locus, including highly polymorphic loci such as HLA loci, BGA loci and HV loci. Embodiments of the disclosed methods are useful in a wide range of applications, including, for example, organ transplantation, personalized medicine, diagnostics, forensics and anthropology.Type: GrantFiled: October 14, 2014Date of Patent: December 25, 2018Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Yu Bai, Wen Fury
-
Patent number: 10083274Abstract: Methods, software, and systems are provided for determining the probability of an overlap set of entities having an overlap size, where the overlap set is independently selected from two sets of non-identical entities. Applications of the invention to microarrays are provided. Probability distributions are provided for determining the probability that the size of an overlap gene set from two different microarrays occurs by chance. Microarray analysis for determining the size of a statistically significant overlap gene set given two different microarrays is described. Overlap set size probability determinations that account for the total number of genes in two different microarrays and not just the common genes are described.Type: GrantFiled: July 12, 2017Date of Patent: September 25, 2018Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Karthikeyan Swaminathan, Wen Fury
-
Publication number: 20180258164Abstract: The present invention relates to the identification of certain biomarkers for use in identifying patients who have, or are likely to develop an IL-33 mediated disease or disorder and who are more likely to respond to therapy with an IL-33 antagonist. The invention also relates to methods of treatment of an IL-33-mediated disease or disorder in a patient by administering an IL-33 antagonist to the patient in need thereof and monitoring the effectiveness of therapy using the biomarkers described herein. Also provided are methods for decreasing the level of at least one biomarker in a subject suffering from an IL-33-mediated disease or disorder, and methods for treating such diseases or disorders according to the expression levels of one or more biomarkers. The methods of the present invention comprise administering to a subject in need thereof a pharmaceutical composition comprising an interleukin-33 antagonist.Type: ApplicationFiled: May 21, 2018Publication date: September 13, 2018Inventors: Jamie M. Orengo, Jeanne Allinne, Wen Fury, Yu Bai
-
Patent number: 10005834Abstract: The present invention relates to the identification of certain biomarkers for use in identifying patients who have, or are likely to develop an IL-33 mediated disease or disorder and who are more likely to respond to therapy with an IL-33 antagonist. The invention also relates to methods of treatment of an IL-33-mediated disease or disorder in a patient by administering an IL-33 antagonist to the patient in need thereof and monitoring the effectiveness of therapy using the biomarkers described herein. Also provided are methods for decreasing the level of at least one biomarker in a subject suffering from an IL-33-mediated disease or disorder, and methods for treating such diseases or disorders according to the expression levels of one or more biomarkers. The methods of the present invention comprise administering to a subject in need thereof a pharmaceutical composition comprising an interleukin-33 antagonist.Type: GrantFiled: October 5, 2016Date of Patent: June 26, 2018Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Jamie M. Orengo, Jeanne Allinne, Wen Fury, Yu Bai
-
Publication number: 20170308642Abstract: Methods, software, and systems are provided for determining the probability of an overlap set of entities having an overlap size, where the overlap set is independently selected from two sets of non-identical entities. Applications of the invention to microarrays are provided. Probability distributions are provided for determining the probability that the size of an overlap gene set from two different microarrays occurs by chance. Microarray analysis for determining the size of a statistically significant overlap gene set given two different microarrays is described. Overlap set size probability determinations that account for the total number of genes in two different microarrays and not just the common genes are described.Type: ApplicationFiled: July 12, 2017Publication date: October 26, 2017Inventors: Karthikeyan Swaminathan, Wen Fury
-
Publication number: 20170096483Abstract: The present invention relates to the identification of certain biomarkers for use in identifying patients who have, or are likely to develop an IL-33 mediated disease or disorder and who are more likely to respond to therapy with an IL-33 antagonist. The invention also relates to methods of treatment of an IL-33-mediated disease or disorder in a patient by administering an IL-33 antagonist to the patient in need thereof and monitoring the effectiveness of therapy using the biomarkers described herein. Also provided are methods for decreasing the level of at least one biomarker in a subject suffering from an IL-33-mediated disease or disorder, and methods for treating such diseases or disorders according to the expression levels of one or more biomarkers. The methods of the present invention comprise administering to a subject in need thereof a pharmaceutical composition comprising an interleukin-33 antagonist.Type: ApplicationFiled: October 5, 2016Publication date: April 6, 2017Inventors: Jamie M. Orengo, Jeanne Allinne, Wen Fury, Yu Bai
-
Publication number: 20150110754Abstract: Provided herein are methods for accurately determining the alleles present at a locus that is broadly applicable to any locus, including highly polymorphic loci such as HLA loci, BGA loci and HV loci. Embodiments of the disclosed methods are useful in a wide range of applications, including, for example, organ transplantation, personalized medicine, diagnostics, forensics and anthropology.Type: ApplicationFiled: October 14, 2014Publication date: April 23, 2015Inventors: Yu Bai, Wen Fury
-
Publication number: 20120323497Abstract: Methods, software, and systems are provided for determining the probability of an overlap set of entities having an overlap size, where the overlap set is independently selected from two sets of non-identical entities. Applications of the invention to microarrays are provided. Probability distributions are provided for determining the probability that the size of an overlap gene set from two different microarrays occurs by chance. Microarray analysis for determining the size of a statistically significant overlap gene set given two different microarrays is described. Overlap set size probability determinations that account for the total number of genes in two different microarrays and not just the common genes are described.Type: ApplicationFiled: August 27, 2012Publication date: December 20, 2012Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Karthikeyan Swaminathan, Wen Fury
-
Patent number: 8255167Abstract: Methods, software, and systems are provided for determining the probability of an overlap set of entities having an overlap size, where the overlap set is independently selected from two sets of non-identical entities. Applications of the invention to microarrays are provided. Probability distributions are provided for determining the probability that the size of an overlap gene set from two different microarrays occurs by chance. Microarray analysis for determining the size of a statistically significant overlap gene set given two different microarrays is described. Overlap set size probability determinations that account for the total number of genes in two different microarrays and not just the common genes are described.Type: GrantFiled: August 4, 2009Date of Patent: August 28, 2012Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Karthikeyan Swaminathan, Wen Fury